Go Pro
→ Wall Street owns 88%. You don’t know the name. (From Monument Traders Alliance) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.01
$0.00
▼
$0.56
$105K-9.0968,411 shs577 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.61
-12.3%		$0.53
$0.37
▼
$1.50
$5.35M1.4959,692 shs237,852 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.03
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$221K0.13284,288 shs45,885 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-54.55%+2,400.00%-99.09%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%-38.33%-96.46%-99.41%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-33.33%-42.86%-20.00%-80.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
$0.01
$0.00
▼
$0.56
$105K-9.0968,411 shs577 shs
Evogene Ltd. stock logo
EVGN
Evogene
$0.61
-12.3%		$0.53
$0.37
▼
$1.50
$5.35M1.4959,692 shs237,852 shs
Inotiv, Inc. stock logo
NOTV
Inotiv
$0.01
-26.0%		$0.03
$0.08
▼
$2.95
$387K3.777.42 million shs243,786 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.10
$221K0.13284,288 shs45,885 shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
0.00%0.00%-54.55%+2,400.00%-99.09%
Evogene Ltd. stock logo
EVGN
Evogene
+10.79%+7.77%+36.82%-7.83%-42.11%
Inotiv, Inc. stock logo
NOTV
Inotiv
0.00%0.00%-38.33%-96.46%-99.41%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-33.33%-42.86%-20.00%-80.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
1.00
SellN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
2.00
Hold$1.5013,413.51% Upside
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CARM, EVGN, NOTV, and SRNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Evogene Ltd. stock logo
EVGN
Evogene
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.01N/AN/A($0.67) per share0.00
Evogene Ltd. stock logo
EVGN
Evogene
$3.85M1.59N/AN/A$1.37 per share0.51
Inotiv, Inc. stock logo
NOTV
Inotiv
$507.36M0.00$0.01 per share0.82$3.96 per share0.00
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%N/A
Evogene Ltd. stock logo
EVGN
Evogene
-$8.48M-$1.39N/AN/AN/A-638.12%-158.82%-80.37%8/18/2026 (Estimated)
Inotiv, Inc. stock logo
NOTV
Inotiv
-$68.62M-$2.53N/AN/AN/A-17.14%-56.77%-8.91%N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A8/18/2026 (Estimated)

Latest CARM, EVGN, NOTV, and SRNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/18/2026Q2 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27N/AN/AN/A$0.33 millionN/A
8/18/2026N/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.42N/AN/AN/A$18.23 millionN/A
5/16/2026Q1 2026
Evogene Ltd. stock logo
EVGN
Evogene
-$0.27-$0.60-$0.33-$0.60$0.35 million$0.33 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Evogene Ltd. stock logo
EVGN
Evogene
N/AN/AN/AN/AN/A
Inotiv, Inc. stock logo
NOTV
Inotiv
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Evogene Ltd. stock logo
EVGN
Evogene
N/A
2.79
2.76
Inotiv, Inc. stock logo
NOTV
Inotiv
N/A
0.27
0.21
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Evogene Ltd. stock logo
EVGN
Evogene
10.40%
Inotiv, Inc. stock logo
NOTV
Inotiv
18.17%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Evogene Ltd. stock logo
EVGN
Evogene
7.40%
Inotiv, Inc. stock logo
NOTV
Inotiv
7.80%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Evogene Ltd. stock logo
EVGN
Evogene
1408.72 million8.07 millionNo Data
Inotiv, Inc. stock logo
NOTV
Inotiv
2,04634.89 million32.17 millionOptionable
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
March 12, 2024  |  news.bloomberglaw.comN
Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case
March 12, 2024  |  wsj.comhttps://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  tmcnet.comhttps://www.tmcnet.com/usubmit/2024/02/27/9968471.htm
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
February 27, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20240227926537/en/virpax-pharmaceuticals-announces-proposed-settlement-of-litigation-with-sorrento-therapeutics-inc.-and-scilex-pharmaceuticals-inc./
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0025 0.00 (0.00%)
As of 08/11/2026 10:29 AM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Evogene stock logo

Evogene NASDAQ:EVGN

$0.61 -0.09 (-12.35%)
As of 11:18 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Inotiv stock logo

Inotiv NASDAQ:NOTV

$0.01 0.00 (-26.00%)
As of 07/17/2026

Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0004 0.00 (0.00%)
As of 11:06 AM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas